217 related articles for article (PubMed ID: 2162953)
1. Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
Groppetti A; Ceresoli G; Mandelli V; Parenti M
J Pharmacol Exp Ther; 1990 Jun; 253(3):950-6. PubMed ID: 2162953
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
4. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
Friedhoff AJ; Bonnet K; Tosengarten H
Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of repeated treatment with L-dopa on dopamine-D1 or -D2 receptors.
Parenti M; Flauto C; Parati E; Vescovi A; Groppetti A
Neuropharmacology; 1986 Mar; 25(3):331-4. PubMed ID: 2871516
[TBL] [Abstract][Full Text] [Related]
6. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
7. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
9. Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.
Asin KE; Bednarz L; Nikkel A; Perner R
J Pharmacol Exp Ther; 1995 Jun; 273(3):1483-90. PubMed ID: 7791123
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
11. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
Roseboom PH; Gnegy ME
Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
[TBL] [Abstract][Full Text] [Related]
12. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
13. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
Lau YS; Runice C; Dowd F
J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
[TBL] [Abstract][Full Text] [Related]
14. Resistance to extrapyramidal effects of opiates in rats chronically treated with SCH 23390.
De Montis GM; Devoto P; Meloni D; Porcella A; Saba P; Tagliamonte A
J Neurosci Res; 1989 Oct; 24(2):286-92. PubMed ID: 2531233
[TBL] [Abstract][Full Text] [Related]
15. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
Onali P; Olianas MC; Gessa GL
Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
[TBL] [Abstract][Full Text] [Related]
16. Chronic sulpiride treatment produces supersensitivity of striatal adenylate cyclase to dopamine in sexually immature or adult castrated rats.
Gnegy ME; Bernabei A; Treisman G
J Pharmacol Exp Ther; 1983 Mar; 224(3):627-33. PubMed ID: 6827485
[TBL] [Abstract][Full Text] [Related]
17. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
18. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Kääriäinen TM; García-Horsman JA; Piltonen M; Männistö PT
Neuroreport; 2009 Feb; 20(3):313-8. PubMed ID: 19188858
[TBL] [Abstract][Full Text] [Related]
19. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
Mura A; Feldon J; Mintz M
Exp Neurol; 2000 Aug; 164(2):322-32. PubMed ID: 10915571
[TBL] [Abstract][Full Text] [Related]
20. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Brannan T; Knott P; Kaufmann H; Yahr M
Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
